Home | About PR | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |   Login 
Pharmacognosy Magazine
Search Article 
  
Advanced search 
 
ORIGINAL ARTICLE
Year : 2013  |  Volume : 5  |  Issue : 3  |  Page : 139-145

UP446, analgesic and anti-inflammatory botanical composition


Unigen Inc., Seattle, Washington, USA

Correspondence Address:
Mesfin Yimam
Unigen, Inc., 3005 1st Avenue, Seattle, Washington 98121
USA
Login to access the Email id

Source of Support: MY conceived and designed, carried out study, data calculation, statistical analysis, data interpretation, and drafted/edited the manuscript. MP assisted in conducting the study. QJ and LB conceived the study, participated in its design, interpreted data, and edited the manuscript. All authors read and approved the final manuscript.,, Conflict of Interest: MY, LB and QJ are current employees of Unigen, as such with financial interest. MP is former employee of Unigen without financial interest. Unigen Inc. is a proprietary ingredient supplier including Scutellaria baicalensis and Acacia catechu.


DOI: 10.4103/0974-8490.112406

Rights and Permissions

Background: Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease. Long-term use of currently available therapies for RA produces adverse effects that limit dosage and duration; hence there is a need for safe and effective alternatives suitable for long term chronic use. UP446, a composition consisting primarily of baicalin from Scutellaria baicalensis Georgi (Family: Lamiaceae) and (+)-catechin from the heartwoods of Acacia catechu (Family: Mimosaceae), has been previously shown to reduce production of eicosanoids and leukotrienes through dual inhibition of cyclooxygenase (COX) and lipoxygenase (LOX) enzymes and to decreased mRNA and protein levels of the proinflammatory cytokines, interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α. Aim: To evaluate the likelihood of UP446 in moderating arthritis and its associated symptoms in an experimental animal model of RA. Materials and Methods: A RA rat model was induced by injecting Freund's complete adjuvant into left and right hind paw and base of the tail. Animals were administered UP446 (50 mg/kg), ibuprofen (150 mg/kg mg/kg) or vehicle by oral gavage 30 min prior to arthritis induction and each day thereafter for 14 days. Result: Animals treated with UP446 showed 23.7, 31.9, 33.4, 29.3, and 33.1% reduction in pain sensitivity; 46.0, 36.7, 33.7, 34.8, and 33.4% reduction in ankle diameter on days 3, 5, 7, 9, and 13; respectively; compared to vehicle. Similarly paw edema was significantly reduced with an average of 30% for the first inflammatory reaction period (day 1-8) followed by 37.1 and 33.6% reduction on day 9 and 13. Conclusion: These data indicate potential benefit of UP446 in alleviating symptoms of RA and support human clinical evaluation of this botanical composition in patients with RA.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3433    
    Printed107    
    Emailed0    
    PDF Downloaded24    
    Comments [Add]    
    Cited by others 3    

Recommend this journal